Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$759.30M+544.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew Toy
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Employees
- 724
- Beta
- 2.48
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.13
Financials
Revenue
$759.30M+544.0%Net Income
$6.43MEBITDA
$7.04MFree Cash Flow
$69.48MEPS (diluted)
$0.01Shares Outstanding (diluted)
557.48M+1217.8%Operating Expenses
$122.80MCash & Debt
$272.58MReturn of Capital
$0.00Dividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.92B | $-85.55M | $-0.17 |
| 2024 | $1.37B | $-43.01M | $-0.09 |
| 2023 | $1.26B | $-213.36M | $-0.45 |
| 2022 | $1.10B | $-339.57M | $-0.71 |
| 2021 | $1.47B | $-587.76M | $-1.25 |
| 2020 | $672.89M | $-136.39M | $-0.23 |
| 2019 | $462.27M | $-363.74M | $-0.90 |
| 2018 | $281.02M | $-201.93M | $-4.81 |
Valuation
CLOVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
170+165.63%Social Signal Score
Mentions (16)
- Newsmarketbeat.com·13d ago·Positive
Clover Health Investments Sees 2027 Growth as Rival Exits New Jersey Clover Health Investments NASDAQ: CLOV expects another year of strong membership growth in 2027, aided by a competitor's exit from its core New Jersey market and what it sees as favorable positioning for its Medicare Advantage plans, Chief Financial Officer Clay Thornton said.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Clover Health Investments, Corp. (CLOV) Presents at 2026 UBS Global Healthcare Conference Transcript Clover Health Investments, Corp. ( CLOV ) 2026 UBS Global Healthcare Conference November 9, 2026 12:30 PM EST Company Participants Clay Thornton - CFO & Principal Financial Officer Conference Call Participants Jonathan Yong - UBS Investment Bank, Research Division Presentation Jonathan Yong UBS Investment Bank, Research Division Thanks for joining us, everyone. With us today, we have Clover Healt…
View source ↗ - Newsseekingalpha.com·16d ago·Positive
…s May Still Be Ahead Clover Health demonstrates robust membership and revenue growth, turning GAAP profitable with improving cohort economics and operating leverage. CLOV maintains a Strong Buy rating, supported by raised 2026 guidance, a confirmed 5-star PPO rating, and a compelling risk-reward profile versus sector peers. Valuation remains attractive at a significant discount to sector medians on forward EV/sales and price-to-sales, despite rapid adjusted EBITDA growth and maturing cohorts.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Clover Health Investments, Corp. (CLOV) Q3 2026 Earnings Call Transcript Clover Health Investments, Corp. (CLOV) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Positive
What Clover Health Investments (CLOV) Said on Its Q3 Earnings Call Clover Health Investments NASDAQ: CLOV raised the lower end of its 2026 financial guidance after reporting a third-quarter profit, and said it expects to achieve its first full year of GAAP net income profitability.
View source ↗ - Newsglobenewswire.com·34d ago·Positive
…ws & World Report's 2027 Medicare Advantage Ratings Across Three States WILMINGTON, Del., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health” or “Clover”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it earned top distinctions across New Jersey, Georgia, and South Carolina in U.S. News & World Report's 2027 Best Insurance Companies for Medicare Advantage (“M…
View source ↗ - News247wallst.com·45d ago·Positive
At 67, He’ll Keep His Clover Medicare Advantage Plan for 2027. The Premium Will Stay $0. The Most He Can Be Billed Will Jump $1,144 A $0 monthly premium sounds like free coverage until you read the pages most people skip. One number buried in the Annual Notice of Change quietly decides how much a serious diagnosis will actually cost in 2027.
View source ↗ - Newsglobenewswire.com·46d ago·Positive
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026 WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, November 4, 2026.
View source ↗ - Newsglobenewswire.com·59d ago·Positive
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
View source ↗ - Newsmarketbeat.com·65d ago·Positive
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
View source ↗ - Newsglobenewswire.com·83d ago·Positive
Clover Health to Participate in Upcoming Investor Conferences WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
View source ↗ - Newsseekingalpha.com·88d ago·Positive
Clover Health Is A 'Buy' Because Of Its AI Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
View source ↗ - Newsseekingalpha.com·99d ago·Positive
Clover Health Investments: Real Turnaround, But Already Priced In Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Clover Health Is Proving Its Profit Model Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
View source ↗ - Newsmarketbeat.com·103d ago·Positive
Clover Health Eyes 2026 GAAP Profit as AI Platform Fuels Medicare Advantage Growth Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.05 per share
Typical surprise +29.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.01 vs $-0.01beat
- Wed, Aug 5$0.05 vs $0.04beat
- Wed, May 6$0.07 vs $0.07beat
- Thu, Feb 26$-0.05 vs $-0.10beat
- Tue, Nov 4$-0.05 vs $0.02miss
- Tue, Aug 5$-0.02 vs $-0.01miss
Estimates and results for CLOV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLOV officers and directors.
- Bought
- —
- Sold
- $8.9m
0 trades
43 trades
- Thornton Joseph Claysold
- Soares Karensold
- Reynoso Jamie L.sold
- Toy Andrewsold
- Soares Karensold
- Thornton Joseph Claysold
- Wai Conradsold
- Reynoso Jamie L.sold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLOV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
